Positively Aware Mavyret

Mavyret

glecaprevir/pibrentasvir (GLE/PIB)

FDA approved for HIV/HCV co-infection.
Genotype
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

Standard Dose

Three tablets once daily with food. Each tablet contains 100 mg of glecaprevir and 40 mg of pibrentasvir for a total daily dose of 300 mg/120 mg. It is important to take all three tablets at the same time—do not separate throughout the day. See treatment duration table at positivelyaware.com/mavyret. The number of weeks on treatment depends on such things as cirrhosis status and previous therapy. Mavyret is FDA approved for use in children age 12 and weighing at least 99 pounds (45 kg).

Mavyret can be used in severe renal impairment, including patients on hemodialysis. NS3/4A protease inhibitors, such as glecaprevir, are contraindicated for patients with moderate or severe liver impairment (Child-Pugh B, C), which is also called decompensated cirrhosis. Using Mavyret in decompensated cirrhosis may cause significantly higher amounts of glecaprevir in the blood and may increase ALT (a liver enzyme).

Take your missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose.

Black Box Warning

Before starting treatment with any direct-acting antiviral (DAA), including Mavyret, patients should take a blood test to check for hepatitis B (HBV) infection. HBV infection could get worse or reactivate during or after DAA treatment, potentially leading to serious liver problems, including liver failure or death. Patients with current or past HBV infection should be monitored during HCV DAA treatment, and some may need to take HBV treatment. See HBV Reactivation for more information and consult your medical provider.

Treatment-naïve patients: If you’ve never taken HCV treatment before, you’ll take it as follows:

Genotype No cirrhosis Compensated Cirrhosis (Child-Pugh A)
1, 2, 3, 4, 5, 6 8 weeks 8 weeks

Treatment-experienced patients: If you have taken HCV treatment before, you’ll take it as follows:

Genotype Previous treatment regimen No cirrhosis Compensated Cirrhosis

(Child-Pugh A)
1 NS5A inhibitor* without prior treatment with an NS3/4A protease inhibitor** 16 weeks 16 weeks
1 NS3/4A protease inhibitor** without prior treatment with an NS5A inhibitor* 12 weeks 12 weeks
1,2,4,5,6 Prior treatment with (peg)interferon, ribavirin and/or sofosbuvir but no other HCV treatment 8 weeks 12 weeks
3 Prior treatment with (peg)interferon, ribavirin and/or sofosbuvir but no other

HCV treatment
16 weeks 16 weeks

* In clinical studies, this included ledipasvir/sofosbuvir or daclatasvir + (peg)interferon + ribavirin. Other NS5A inhibitors include elbasvir, velpatasvir, and ombitasvir.

** In clinical studies, this included simeprevir + sofosbuvir, simeprevir, boceprevir, or telaprevir + (peg)interferon + ribavirin.

Manufacturer

AbbVie

AWP

$15,840 / month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information